SlideShare a Scribd company logo
“ANALGESICS”
Presented by:
Dr. Manish Chandila
JR-2
PAIN
What is pain?
• A protective mechanism to warn of damage or the
presence of disease
• Part of the normal healing process
ANALGESICS
I. Opioid (narcotic) analgesics
1. Agonists of opioid receptors – morphine hydrochloride,
promedol, omnopon, fentanyl, codeine;
2. Agonists – antagonists and partial agonists of opioid receptors
– pentazocin, buprenorphine.
II. Non-opioid analgesics and non steroidal anti-
inflammatory drugs - NSAIDs
Acetylsalicylic acid, paracetamol, analgin, indometacin,
butadion, ibuprofen, pyroxicam, diclofenac-sodium, ketorolac,
ketoprofen.
III. Substances with mixed mechanism of action
(Opioid and non-opioid components)- Tramadole
The structures that take part in perception of pain:
thalamus, hypothalamus, reticular formation, limbic
system, occipital and frontal areas of cortex
System which conducts and perceives pain
NOCICEPTIVE
Classification of Pain
By Onset and Duration
 Acute pain
 Sudden in onset
 Usually subsides once treated
 Chronic pain
 Persistent or recurring
 Often difficult to treat
Major Sources of Pain
Source Area Involved Characteristics Treatment
Somatic body
framework
throbbing,
stabbing
narcotics,
NSAIDS
Visceral kidneys,
intestines,
liver
aching,
throbbing,
sharp, crampy
narcotics,
NSAIDS
Neuropathic Nerves burning,
numbing,
tingling
narcotics,
NSAIDS,
antidepressants,
anticonvulsants
History of Opioids
•Opium is extracted from poppy seeds (Papaver
somniforum)
•Used for thousands of years to produce:
•Euphoria
•Analgesia
•Sedation
•Relief from diarrhea
•Cough suppression
History cont’d
•Used medicinally and recreationally from
early Greek and Roman times
•Opium and laudanum (opium combined
with alcohol) were used to treat almost all
known diseases
Friedrich Wilhelm Adam
Sertürner, a German
pharmacist, isolated
Morphine from opium,
in 1805.
Morpheus
is the Greek god of
dreams and sleep.
History and Background
•Invention of the hypodermic needle in 1856 produced
drug abusers who self administered opioids by
injection
•Controlling the widespread use of opioids has been
unsuccessful because of the euphoria, tolerance and
physiological dependence that opioids produce
OPIOID RECEPTORS
• group of G-protein coupled receptors with opioids as
ligands.
•The endogenous opioids are dynorphins, enkephalins,
endorphins, endomorphins and nociceptin.
Subtypes of opireceptors:
mu, delta, kappa, epsilon, sigma
Morphine CNS
Depressant effects
• Analgesia
• Indifference to surroundings
• Mood and subjective effects
• Depression of respiration
• Cough centre
• Temperature regulating centre
• Vasomotor centre
Stimulate effects
• CTZ (nausea, vimiting)
• Edinger Wesphal nucleus
(III nerve –producing miosis)
• Vagal centre (bradycardia)
• Certain cortical areas and
hippocampal
Morphine can be used as an analgesic to relieve:
pain in myocardial infarction
pain associated with surgical conditions, pre- and
postoperatively (pre-anesthetic medication, balanced
anesthesia, surgical analgesia)
pain associated with trauma, burns
severe chronic pain, e.g., cancer
pain from kidney stones, renal colic, ureterolithiasis, etc
(pain may be valuable for diagnosis: should not be relived by analgesic unless proper
assessment of the patient has been done)
traumas of thorax accompanied by cough (morphine depresses central links of
coughing reflexes)
Acute left-ventricular cardiac failure
(cardiac asthma)
Reduce preload on heard due to vasodilatation
Tending to shift blood from pulmonary to systemic circuit;
relieves pulmonary congestion and edema
Allays air hunger by depressing respiratory centre
Cuts down sympathetic stimulation by calming the patient
Applications in Dentistry
•Narcotic (opioid) analgesics are extremely
effective in reducing acute dental and
postoperative pain.
•The narcotic analgesics have established a niche
for the treatment of pain in those situations
where the NSAIDs are less effective.
• Hydrocodone, oxycodone, codeine, and
occasionally meperidine are the narcotics used
to treat dental pain.
MORPHINE HYDROCHLORIDE
ROUTES OF ADMINISTRATION
 subcutaneously and intramuscularly
(analgesic action after 10-15 min)
 oral administration – presystemic elimination
( 20-60 % enters general blood circulation)
 sublingually – quick absorption
 i.v. is indicated even in emergency
 Epidural or intrathecal ( into the spinal canal ) injection produces
segmental analgesia lasting 12 hours without affecting other
sensory, motor or autonomic modalities
Duration of analgesic action – 4-6 hours
Maximum single dose of morphine is 0,02 g,
maximum daily dose – 0,05 g
Side effects of morphine
 Respiratory depression
 Vomiting (excitation of starting zone of
vomiting center)
 bradycardia (increasing of tone of n. vagus
nuclei)
 spasm of sphincters of gastro-intestinal tract
accompanied by constipations
 increasing of tone of smooth musculature of
urinary and bile-excreting tracts (retentions
of urination, bile stasis)
 Decreasing of BP
CONTRAINDICATIONS FOR ADMINISTRATION
OF MORPHINE
acute respiratory depression
renal failure (due to accumulation of the metabolites
morphine-3-glucuronide and morphine-6-glucuronide)
chemical toxicity (potentially lethal in low tolerance
subjects)
raised intracranial pressure, including head injury (risk of
worsening respiratory depression)
Biliary colic
Precaution
pain that accompanies chronic inflammatory pain
children before the age of 2 years
Tolerance
•Tolerance is a diminished responsiveness to the drug’s
action that is seen with many compounds
•Tolerance can be demonstrated by a decreased effect
from a constant dose of drug or by an increase in the
minimum drug dose required to produce a given level
of effect
•Physiological tolerance involves changes in the
binding of a drug to receptors or changes in receptor
transductional processes related to the drug of action
•This type of tolerance occurs in opioids
Addiction
•Physical dependence
•Physiological dependence
•Withdrawal reactions
Tolerance and Dependence
Withdrawl Reactions
Acute Action
• Analgesia
• Respiratory Depression
• Euphoria
• Relaxation and sleep
• Tranquilization
• Decreased blood pressure
• Constipation
• Pupillary constriction
• Hypothermia
• Drying of secretions
• Reduced sex drive
• Flushed and warm skin
Withdrawl Sign
• Pain and irritability
• Hyperventilation
• Dysphoria and depression
• Restlessness and insomnia
• Fearfulness and hostility
• Increased blood pressure
• Diarrhea
• Pupillary dilation
• Hyperthermia
• Lacrimation, runny nose
• Spontaneous ejaculation
• Chilliness and “gooseflesh”
OMNOPON
•contains mixture if opium alkaloids
(48-50% morphine)
•does not cause spasms of smooth musculature,
as it contains alkaloids of isoquinoline raw
•is used for analgesia according to all the
indications of morphine hydrochloride, for
example, colics
Promedol (trimeperidine)
•produces similar effects to other opioids, such
as analgesia and sedation, along with side
effects such as nausea, itching, vomiting and
respiratory depression which may be harmful or
fatal.
•duration of analgesic action - 3-4 hours
•moderate spasmolytic influence on smooth
musculature of internal organs
•stimulation of rhythmic contractions of uterus
•can be used for analgesia
•in case of pain syndrome connected with
spasms of smooth musculature
Fentanyl
•synthetic opioid analgesic of short action
•analgesic activity is 300 times higher than of
morphine
•analgesic effect after intravenous introduction –
after 1-3 min, lasts for 15-30 min
•used with neuroleptic droperidol (complex drug –
“talamonal”) for neuroleptanalgesia
Fentanyl transdermal system
•should be used for long-
term (chronic) pain
requiring continuous
narcotic pain
•Is designed to release the
drug into the skin at a
constant rate ranging from
25 to 100 micrograms/h
Codeine
 opium alkaloid
 analgesic action is not strong, but anticough effect is
considerable
 administered as an anticough drug of central action
 combination with non opiod analgesics
(eg. Paracetamol) is supra-additive
Pentazocin
 agonist-antagonist of opioid receptors
 comparatively with morphine, it is a bit less
dangerous in the aspect of addiction
development
 indicated in case of pain of medium intensity in
such conditions like other opioid analgesics. In
case of strong pain its administration is limited
as in case of increasing of dose of the drug
excitation appears
 it can cause increasing of blood pressure and
tachycardia that’s why it’s not advised to use in
case of acute myocardium infarction
 if it is administered for people with narcotic
addiction manifestations of abstinence develop
Buprenorphine
• Partly agonist of mu-opioid receptors
• Acts longer than morphine (approximately 6 hours)
• Analgesic activity is higher than of morphine, that’s why it’s
used in doses of 0,3-0,6 mg
• In case of breathing depression, which it causes, naloxon is less
effective since buprenorphine is slowly released from the
connection with mu-receptors
• Indicated for pain decreasing in the same situations as other
narcotic analgesics
• May be used for detoxication and supporting treatment of
individuals who is addicted to heroine
Acute poisoning with opioid analgesics
•Respiratory Depression
•Euphoria
•Relaxation and sleep
•Tranquilization
•Decreased blood pressure
•Constipation
•Pupillary constriction
•Hypothermia
•Drying of secretions
•Flushed and warm skin
Triad in case poisoning
with morphine
Acute miosis
(Pinpoint
pupils)
Cheyne Stokes
respiration
deep tendon
reflexes
increased
Treatment of acute poisoning
 Naloxon (antagonist of opioid receptors)
intravenously - 0,4-1,2 mg
general dose of naloxon should not overcome 10 mg
 stomach lavage (for morphine enterohepatic circulation is
typical) with 0,05-0,1% solution of potassium
permanganate and 0,5 % tannin solution
 suspension of 20-30 g of activated charcoal
 salt laxative agents (sodium sulfate)
 forced diuresis
 atropine sulfate
 inhalation of carbogen (5-7 % СО2 and 93-95 % O2)
NON-OPIOID
ANALGESICS
Pharmacodynamic Effects
•Analgesic
•Antipyretic
•Anti-inflammatory
(except paracetamol)
Mechanism of action of non-opioid
analgesics
•depression of cyclooxygenases activity
•decreasing of prostaglandins synthesis in
peripheral tissues and in central nervous
system
•decreasing of sensitivity of nervous endings
and depression of transmission of
nociceptive impulses on the level of CNS
structures
•pain-relieving action of non-opioid
analgesics is partly connected with their anti-
inflammatory activity
Effects of COX Inhibition
by Most NSAIDS
COX-1
Gastric ulcers
Bleeding
Acute renal failure
COX-2
Reduce inflammation
Reduce pain
Reduce fever
NSAIDs : anti-platelet—decreases ability of blood to clot
COX Enzyme:Prostaglandin Effects
COX-1: beneficial COX-2: harmful
Peripheral injury
site
Inflammation
Brain Modulate pain
perception
Promote fever
(hypothalamus)
Stomach protect mucosa
Platelets aggregation
Kidney vasodilation
Indications for administration of non-
narcotic analgesics
 headache
 toothache
 backache
 neuralgias
 pulled muscles
 joint pain
 dysmenorrhea
for potentiating of their action – combinations
paracetamol with codeine,
metamizol with dimedrol, metamizol with codeine
Applications in Dentistry
• Toothache
• Post extraction pain
• Periodontitis
• Neuritis
• Stomatitis
• Arthritis
• Local usage as keratoplatic agents for hyperkeratosis, hyperesthesia
Paracetamol
(Acetaminophen)
• analgesic and antipyretic drug
• maximal effect if the drug is introduced orally – after 2 hours,
lasts approximately for 4 hours
• in case of durable administration of big doses – damaging of
liver and kidneys, production of met-hemoglobin
Paracetamol (Acetaminophen)
N-Acetyl-P-Aminophenol
Classification: analgesic, antipyretic, misc.
not an NSAID
Mechanism: inhibits prostaglandin synthesis
via CNS inhibition of COX (not peripheral)-
doesn’t promote ulcers, bleeding or renal failure;
peripherally blocks generation of pain impulses,
inhibits hypothalamic heat-regulation center
Paracetamol
•Tablets
•Suppositories
•Syrups
•Soluble tablets
•Capsules
PARACETAMOL
Pharmacokinetics: Paracetamol
Metabolism: major and minor pathways
Half-life: 1-3 hours
Time to peak concentration: 10-60 min
Treatment for overdose: Acetylcysteine
Paracetamol : Liver Metabolism
1. Major pathway —Majority of drug is metabolized
to produce a non-toxic metabolite
2. Minor pathway —Produces a highly reactive
intermediate (acetylimidoquinone) that conjugates
with glutathione and is inactivated.
•At toxic PARACETAMOL levels, minor pathway
metabolism cannot keep up (liver’s supply of
glutathione is limited), causing an increase in the
reactive intermediate which leads to hepatic toxicity
and necrosis
Acetylsalicylic acid
 Blocks irreversibly COX
 As antipyretic and analgesic
drug – 0,25 and 0,5 g per time
 As an anti-inflammatory – 3-4 g
per day (for arthritis,
myocarditis, pleuritis, bronchitis
etc.
 As platelets inhibitor - for
prophylaxis of thrombus-
formation (in case of ischemic
heart disease, thrombophlebitis
etc.) – daily dose – 80-100 mg
Pharmacokinetics: ASA
Absorption: from stomach and intestine
Distribution: readily, into most fluids/tissues
Metabolism : primarily hepatic
•ASA contraindicated for use in children with viral
fever –can lead to Reye’s Syndrome
•Fatal overdose is possible
Similar pharmacokinetics for ibuprofen and related NSAIDs
Analgin
(metamizol-sodium)
Baralgin (maxigan, spazgan, spazmalgon,
trigan)
metamizol-sodium +pitophenon hydrochloride+pheniverinium
bromide
Ampoules
tablets
suppositories
Analgesic
and
spasmolytic
activity
Traditional and selective COX-2
inhibitors
Ketorolak (ketanov)
•according to analgesic activity it
prevails over effect of acetylsalicylic
acid, indometacin and equals to
opioid analgesics
•moderate anti-inflammatory,
antipyretic and anti-aggregate effects
•high effectiveness in case of pain in
postoperative period, in oncology,
during child delivery, traumas, colic
•i/m, i/v, orally
NOT indicated
for chronic pain syndrome
Ketoprophen (ketonal)
• strong analgesic, anti-inflammatory and antipyretic agent
• administered in case of arthroses and arthritis, ancilizing
spondilitis, pain of different genesis (after surgeries, in case
of traumas, painful menstruations etc.)
• administered orally, intramuscularly, in forms of
suppositories and ointments
TRAMADOL
Analgesic activity is similar to the activity
of morphine
Abuse potential is low
Less respiratory depression
Hemodynamic effects are minimal
In case of intravenous administration effect
develops after 5-10 min, if administered
orally – after 30-40 min, action lasts for
3-5 hours.
Tramadol possesses agonist actions at the μ-opioid receptor
and affects reuptake at the noradrenergic and serotonergic systems
ADMINISTRATION OF TRAMADOL
1. Surgery, traumatology, gynecology,
neurology, urology, oncology
2. For all kinds of acute and chronic pain of
moderate and considerable intensity,
including neuralgias, postoperative,
traumatic pain
diagnostic and therapeutic interventions
oncologic pathology
THANK YOU!!

More Related Content

Similar to 6188588.ppt

Presentation by Dr.suraj kurmi
Presentation by Dr.suraj kurmiPresentation by Dr.suraj kurmi
Presentation by Dr.suraj kurmi
Suraj Kurmi
 
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptxChp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
MahnoorFatima92
 
narcotics
narcoticsnarcotics
narcotics
Ikenna Godwin
 
Non narcotic: Agonist antagonist
Non narcotic: Agonist antagonistNon narcotic: Agonist antagonist
Non narcotic: Agonist antagonist
SONALI PAWAR
 
Opioids
OpioidsOpioids
Opioids
Du'a Al-Zu'bi
 
Dolor.pdf
Dolor.pdfDolor.pdf
Dolor.pdf
Raul D-v
 
Opioids
OpioidsOpioids
Pain therapy and clinical aspects
Pain therapy and clinical aspectsPain therapy and clinical aspects
Pain therapy and clinical aspects
Deepak Chinagi
 
Opioids Analgesics
Opioids AnalgesicsOpioids Analgesics
Opioids Analgesics
Dr.Arka Mondal
 
Opiod analgesics
Opiod analgesicsOpiod analgesics
Opiod analgesics
Komalantil3
 
Analgesics.pptx
Analgesics.pptxAnalgesics.pptx
Analgesics.pptx
MensurShafie1
 
analgesics-and-pain-control-in-dentistry.pptx
analgesics-and-pain-control-in-dentistry.pptxanalgesics-and-pain-control-in-dentistry.pptx
analgesics-and-pain-control-in-dentistry.pptx
VinodThangaswamyS
 
Analgesics
AnalgesicsAnalgesics
Analgesics
ankit4089
 
analgesics and dentistry
analgesics and dentistryanalgesics and dentistry
analgesics and dentistry
Mehul Shinde
 
General Anaethetics & Pre-anaethetics.pptx
General Anaethetics & Pre-anaethetics.pptxGeneral Anaethetics & Pre-anaethetics.pptx
General Anaethetics & Pre-anaethetics.pptx
Manish Gautam
 
Narcotic analgesics Group 5.pptx
Narcotic analgesics Group 5.pptxNarcotic analgesics Group 5.pptx
Narcotic analgesics Group 5.pptx
WrapzeeTech
 
Opioid Analgesics & Antagonists.ppt
Opioid Analgesics & Antagonists.pptOpioid Analgesics & Antagonists.ppt
Opioid Analgesics & Antagonists.ppt
Lilian523287
 
Analgesics.pptx
Analgesics.pptxAnalgesics.pptx
Analgesics.pptx
TakaleBulo
 

Similar to 6188588.ppt (20)

Presentation by Dr.suraj kurmi
Presentation by Dr.suraj kurmiPresentation by Dr.suraj kurmi
Presentation by Dr.suraj kurmi
 
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptxChp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
Chp no 4 Drugs affecting pain & inflammation - NSAIDs.pptx
 
Chemistryandthe brain
Chemistryandthe brainChemistryandthe brain
Chemistryandthe brain
 
narcotics
narcoticsnarcotics
narcotics
 
Non narcotic: Agonist antagonist
Non narcotic: Agonist antagonistNon narcotic: Agonist antagonist
Non narcotic: Agonist antagonist
 
Opioids
OpioidsOpioids
Opioids
 
Dolor.pdf
Dolor.pdfDolor.pdf
Dolor.pdf
 
Opioids
OpioidsOpioids
Opioids
 
Pain therapy and clinical aspects
Pain therapy and clinical aspectsPain therapy and clinical aspects
Pain therapy and clinical aspects
 
Opioids Analgesics
Opioids AnalgesicsOpioids Analgesics
Opioids Analgesics
 
Pain drugs
Pain drugsPain drugs
Pain drugs
 
Opiod analgesics
Opiod analgesicsOpiod analgesics
Opiod analgesics
 
Analgesics.pptx
Analgesics.pptxAnalgesics.pptx
Analgesics.pptx
 
analgesics-and-pain-control-in-dentistry.pptx
analgesics-and-pain-control-in-dentistry.pptxanalgesics-and-pain-control-in-dentistry.pptx
analgesics-and-pain-control-in-dentistry.pptx
 
Analgesics
AnalgesicsAnalgesics
Analgesics
 
analgesics and dentistry
analgesics and dentistryanalgesics and dentistry
analgesics and dentistry
 
General Anaethetics & Pre-anaethetics.pptx
General Anaethetics & Pre-anaethetics.pptxGeneral Anaethetics & Pre-anaethetics.pptx
General Anaethetics & Pre-anaethetics.pptx
 
Narcotic analgesics Group 5.pptx
Narcotic analgesics Group 5.pptxNarcotic analgesics Group 5.pptx
Narcotic analgesics Group 5.pptx
 
Opioid Analgesics & Antagonists.ppt
Opioid Analgesics & Antagonists.pptOpioid Analgesics & Antagonists.ppt
Opioid Analgesics & Antagonists.ppt
 
Analgesics.pptx
Analgesics.pptxAnalgesics.pptx
Analgesics.pptx
 

More from Saumya Singh

neuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
neuromonitoringinanesthesia-150217064704-conversion-gate02.pdfneuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
neuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
Saumya Singh
 
analgesics-presentation.pptx
analgesics-presentation.pptxanalgesics-presentation.pptx
analgesics-presentation.pptx
Saumya Singh
 
BIOPROGRESSIVE THERAPY IV.ppt
BIOPROGRESSIVE THERAPY IV.pptBIOPROGRESSIVE THERAPY IV.ppt
BIOPROGRESSIVE THERAPY IV.ppt
Saumya Singh
 
100013603 [Repaired] [Auto-saved].pptx
100013603 [Repaired] [Auto-saved].pptx100013603 [Repaired] [Auto-saved].pptx
100013603 [Repaired] [Auto-saved].pptx
Saumya Singh
 
BURSTONE SOFT TISSUE ANALYSIS.pptx
BURSTONE SOFT TISSUE ANALYSIS.pptxBURSTONE SOFT TISSUE ANALYSIS.pptx
BURSTONE SOFT TISSUE ANALYSIS.pptx
Saumya Singh
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
Saumya Singh
 
PULMONARY FUNCT TEST.pptx
PULMONARY FUNCT TEST.pptxPULMONARY FUNCT TEST.pptx
PULMONARY FUNCT TEST.pptx
Saumya Singh
 
APOS Trends in Orthodontics-3.pptx
APOS Trends in Orthodontics-3.pptxAPOS Trends in Orthodontics-3.pptx
APOS Trends in Orthodontics-3.pptx
Saumya Singh
 
BEGGS 2.pptx
BEGGS 2.pptxBEGGS 2.pptx
BEGGS 2.pptx
Saumya Singh
 
roth.ppt
roth.pptroth.ppt
roth.ppt
Saumya Singh
 
Management of openbite 2.ppt
Management of openbite 2.pptManagement of openbite 2.ppt
Management of openbite 2.ppt
Saumya Singh
 
APOS Trends in Orthodontics-2.pptx
APOS Trends in Orthodontics-2.pptxAPOS Trends in Orthodontics-2.pptx
APOS Trends in Orthodontics-2.pptx
Saumya Singh
 
262054548-Late-Lower-Incisor-Crowding.pdf
262054548-Late-Lower-Incisor-Crowding.pdf262054548-Late-Lower-Incisor-Crowding.pdf
262054548-Late-Lower-Incisor-Crowding.pdf
Saumya Singh
 
BPT part 1.ppt
BPT part 1.pptBPT part 1.ppt
BPT part 1.ppt
Saumya Singh
 
POSTER ON AI.pdf
POSTER ON AI.pdfPOSTER ON AI.pdf
POSTER ON AI.pdf
Saumya Singh
 

More from Saumya Singh (15)

neuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
neuromonitoringinanesthesia-150217064704-conversion-gate02.pdfneuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
neuromonitoringinanesthesia-150217064704-conversion-gate02.pdf
 
analgesics-presentation.pptx
analgesics-presentation.pptxanalgesics-presentation.pptx
analgesics-presentation.pptx
 
BIOPROGRESSIVE THERAPY IV.ppt
BIOPROGRESSIVE THERAPY IV.pptBIOPROGRESSIVE THERAPY IV.ppt
BIOPROGRESSIVE THERAPY IV.ppt
 
100013603 [Repaired] [Auto-saved].pptx
100013603 [Repaired] [Auto-saved].pptx100013603 [Repaired] [Auto-saved].pptx
100013603 [Repaired] [Auto-saved].pptx
 
BURSTONE SOFT TISSUE ANALYSIS.pptx
BURSTONE SOFT TISSUE ANALYSIS.pptxBURSTONE SOFT TISSUE ANALYSIS.pptx
BURSTONE SOFT TISSUE ANALYSIS.pptx
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
 
PULMONARY FUNCT TEST.pptx
PULMONARY FUNCT TEST.pptxPULMONARY FUNCT TEST.pptx
PULMONARY FUNCT TEST.pptx
 
APOS Trends in Orthodontics-3.pptx
APOS Trends in Orthodontics-3.pptxAPOS Trends in Orthodontics-3.pptx
APOS Trends in Orthodontics-3.pptx
 
BEGGS 2.pptx
BEGGS 2.pptxBEGGS 2.pptx
BEGGS 2.pptx
 
roth.ppt
roth.pptroth.ppt
roth.ppt
 
Management of openbite 2.ppt
Management of openbite 2.pptManagement of openbite 2.ppt
Management of openbite 2.ppt
 
APOS Trends in Orthodontics-2.pptx
APOS Trends in Orthodontics-2.pptxAPOS Trends in Orthodontics-2.pptx
APOS Trends in Orthodontics-2.pptx
 
262054548-Late-Lower-Incisor-Crowding.pdf
262054548-Late-Lower-Incisor-Crowding.pdf262054548-Late-Lower-Incisor-Crowding.pdf
262054548-Late-Lower-Incisor-Crowding.pdf
 
BPT part 1.ppt
BPT part 1.pptBPT part 1.ppt
BPT part 1.ppt
 
POSTER ON AI.pdf
POSTER ON AI.pdfPOSTER ON AI.pdf
POSTER ON AI.pdf
 

Recently uploaded

Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
PedroFerreira53928
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
Nguyen Thanh Tu Collection
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
Vivekanand Anglo Vedic Academy
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptxMARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
bennyroshan06
 

Recently uploaded (20)

Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptxMARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
 

6188588.ppt

  • 2. PAIN What is pain? • A protective mechanism to warn of damage or the presence of disease • Part of the normal healing process
  • 3. ANALGESICS I. Opioid (narcotic) analgesics 1. Agonists of opioid receptors – morphine hydrochloride, promedol, omnopon, fentanyl, codeine; 2. Agonists – antagonists and partial agonists of opioid receptors – pentazocin, buprenorphine. II. Non-opioid analgesics and non steroidal anti- inflammatory drugs - NSAIDs Acetylsalicylic acid, paracetamol, analgin, indometacin, butadion, ibuprofen, pyroxicam, diclofenac-sodium, ketorolac, ketoprofen. III. Substances with mixed mechanism of action (Opioid and non-opioid components)- Tramadole
  • 4. The structures that take part in perception of pain: thalamus, hypothalamus, reticular formation, limbic system, occipital and frontal areas of cortex System which conducts and perceives pain NOCICEPTIVE
  • 5. Classification of Pain By Onset and Duration  Acute pain  Sudden in onset  Usually subsides once treated  Chronic pain  Persistent or recurring  Often difficult to treat
  • 6. Major Sources of Pain Source Area Involved Characteristics Treatment Somatic body framework throbbing, stabbing narcotics, NSAIDS Visceral kidneys, intestines, liver aching, throbbing, sharp, crampy narcotics, NSAIDS Neuropathic Nerves burning, numbing, tingling narcotics, NSAIDS, antidepressants, anticonvulsants
  • 7. History of Opioids •Opium is extracted from poppy seeds (Papaver somniforum) •Used for thousands of years to produce: •Euphoria •Analgesia •Sedation •Relief from diarrhea •Cough suppression
  • 8. History cont’d •Used medicinally and recreationally from early Greek and Roman times •Opium and laudanum (opium combined with alcohol) were used to treat almost all known diseases
  • 9. Friedrich Wilhelm Adam Sertürner, a German pharmacist, isolated Morphine from opium, in 1805. Morpheus is the Greek god of dreams and sleep.
  • 10. History and Background •Invention of the hypodermic needle in 1856 produced drug abusers who self administered opioids by injection •Controlling the widespread use of opioids has been unsuccessful because of the euphoria, tolerance and physiological dependence that opioids produce
  • 11. OPIOID RECEPTORS • group of G-protein coupled receptors with opioids as ligands. •The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. Subtypes of opireceptors: mu, delta, kappa, epsilon, sigma
  • 12. Morphine CNS Depressant effects • Analgesia • Indifference to surroundings • Mood and subjective effects • Depression of respiration • Cough centre • Temperature regulating centre • Vasomotor centre Stimulate effects • CTZ (nausea, vimiting) • Edinger Wesphal nucleus (III nerve –producing miosis) • Vagal centre (bradycardia) • Certain cortical areas and hippocampal
  • 13. Morphine can be used as an analgesic to relieve: pain in myocardial infarction pain associated with surgical conditions, pre- and postoperatively (pre-anesthetic medication, balanced anesthesia, surgical analgesia) pain associated with trauma, burns severe chronic pain, e.g., cancer pain from kidney stones, renal colic, ureterolithiasis, etc (pain may be valuable for diagnosis: should not be relived by analgesic unless proper assessment of the patient has been done) traumas of thorax accompanied by cough (morphine depresses central links of coughing reflexes)
  • 14. Acute left-ventricular cardiac failure (cardiac asthma) Reduce preload on heard due to vasodilatation Tending to shift blood from pulmonary to systemic circuit; relieves pulmonary congestion and edema Allays air hunger by depressing respiratory centre Cuts down sympathetic stimulation by calming the patient
  • 15. Applications in Dentistry •Narcotic (opioid) analgesics are extremely effective in reducing acute dental and postoperative pain. •The narcotic analgesics have established a niche for the treatment of pain in those situations where the NSAIDs are less effective. • Hydrocodone, oxycodone, codeine, and occasionally meperidine are the narcotics used to treat dental pain.
  • 16. MORPHINE HYDROCHLORIDE ROUTES OF ADMINISTRATION  subcutaneously and intramuscularly (analgesic action after 10-15 min)  oral administration – presystemic elimination ( 20-60 % enters general blood circulation)  sublingually – quick absorption  i.v. is indicated even in emergency  Epidural or intrathecal ( into the spinal canal ) injection produces segmental analgesia lasting 12 hours without affecting other sensory, motor or autonomic modalities Duration of analgesic action – 4-6 hours Maximum single dose of morphine is 0,02 g, maximum daily dose – 0,05 g
  • 17. Side effects of morphine  Respiratory depression  Vomiting (excitation of starting zone of vomiting center)  bradycardia (increasing of tone of n. vagus nuclei)  spasm of sphincters of gastro-intestinal tract accompanied by constipations  increasing of tone of smooth musculature of urinary and bile-excreting tracts (retentions of urination, bile stasis)  Decreasing of BP
  • 18. CONTRAINDICATIONS FOR ADMINISTRATION OF MORPHINE acute respiratory depression renal failure (due to accumulation of the metabolites morphine-3-glucuronide and morphine-6-glucuronide) chemical toxicity (potentially lethal in low tolerance subjects) raised intracranial pressure, including head injury (risk of worsening respiratory depression) Biliary colic Precaution pain that accompanies chronic inflammatory pain children before the age of 2 years
  • 19. Tolerance •Tolerance is a diminished responsiveness to the drug’s action that is seen with many compounds •Tolerance can be demonstrated by a decreased effect from a constant dose of drug or by an increase in the minimum drug dose required to produce a given level of effect •Physiological tolerance involves changes in the binding of a drug to receptors or changes in receptor transductional processes related to the drug of action •This type of tolerance occurs in opioids
  • 22. Withdrawl Reactions Acute Action • Analgesia • Respiratory Depression • Euphoria • Relaxation and sleep • Tranquilization • Decreased blood pressure • Constipation • Pupillary constriction • Hypothermia • Drying of secretions • Reduced sex drive • Flushed and warm skin Withdrawl Sign • Pain and irritability • Hyperventilation • Dysphoria and depression • Restlessness and insomnia • Fearfulness and hostility • Increased blood pressure • Diarrhea • Pupillary dilation • Hyperthermia • Lacrimation, runny nose • Spontaneous ejaculation • Chilliness and “gooseflesh”
  • 23. OMNOPON •contains mixture if opium alkaloids (48-50% morphine) •does not cause spasms of smooth musculature, as it contains alkaloids of isoquinoline raw •is used for analgesia according to all the indications of morphine hydrochloride, for example, colics
  • 24. Promedol (trimeperidine) •produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting and respiratory depression which may be harmful or fatal. •duration of analgesic action - 3-4 hours •moderate spasmolytic influence on smooth musculature of internal organs •stimulation of rhythmic contractions of uterus •can be used for analgesia •in case of pain syndrome connected with spasms of smooth musculature
  • 25. Fentanyl •synthetic opioid analgesic of short action •analgesic activity is 300 times higher than of morphine •analgesic effect after intravenous introduction – after 1-3 min, lasts for 15-30 min •used with neuroleptic droperidol (complex drug – “talamonal”) for neuroleptanalgesia
  • 26. Fentanyl transdermal system •should be used for long- term (chronic) pain requiring continuous narcotic pain •Is designed to release the drug into the skin at a constant rate ranging from 25 to 100 micrograms/h
  • 27. Codeine  opium alkaloid  analgesic action is not strong, but anticough effect is considerable  administered as an anticough drug of central action  combination with non opiod analgesics (eg. Paracetamol) is supra-additive
  • 28. Pentazocin  agonist-antagonist of opioid receptors  comparatively with morphine, it is a bit less dangerous in the aspect of addiction development  indicated in case of pain of medium intensity in such conditions like other opioid analgesics. In case of strong pain its administration is limited as in case of increasing of dose of the drug excitation appears  it can cause increasing of blood pressure and tachycardia that’s why it’s not advised to use in case of acute myocardium infarction  if it is administered for people with narcotic addiction manifestations of abstinence develop
  • 29. Buprenorphine • Partly agonist of mu-opioid receptors • Acts longer than morphine (approximately 6 hours) • Analgesic activity is higher than of morphine, that’s why it’s used in doses of 0,3-0,6 mg • In case of breathing depression, which it causes, naloxon is less effective since buprenorphine is slowly released from the connection with mu-receptors • Indicated for pain decreasing in the same situations as other narcotic analgesics • May be used for detoxication and supporting treatment of individuals who is addicted to heroine
  • 30. Acute poisoning with opioid analgesics •Respiratory Depression •Euphoria •Relaxation and sleep •Tranquilization •Decreased blood pressure •Constipation •Pupillary constriction •Hypothermia •Drying of secretions •Flushed and warm skin
  • 31. Triad in case poisoning with morphine Acute miosis (Pinpoint pupils) Cheyne Stokes respiration deep tendon reflexes increased
  • 32. Treatment of acute poisoning  Naloxon (antagonist of opioid receptors) intravenously - 0,4-1,2 mg general dose of naloxon should not overcome 10 mg  stomach lavage (for morphine enterohepatic circulation is typical) with 0,05-0,1% solution of potassium permanganate and 0,5 % tannin solution  suspension of 20-30 g of activated charcoal  salt laxative agents (sodium sulfate)  forced diuresis  atropine sulfate  inhalation of carbogen (5-7 % СО2 and 93-95 % O2)
  • 35. Mechanism of action of non-opioid analgesics •depression of cyclooxygenases activity •decreasing of prostaglandins synthesis in peripheral tissues and in central nervous system •decreasing of sensitivity of nervous endings and depression of transmission of nociceptive impulses on the level of CNS structures •pain-relieving action of non-opioid analgesics is partly connected with their anti- inflammatory activity
  • 36.
  • 37. Effects of COX Inhibition by Most NSAIDS COX-1 Gastric ulcers Bleeding Acute renal failure COX-2 Reduce inflammation Reduce pain Reduce fever NSAIDs : anti-platelet—decreases ability of blood to clot
  • 38. COX Enzyme:Prostaglandin Effects COX-1: beneficial COX-2: harmful Peripheral injury site Inflammation Brain Modulate pain perception Promote fever (hypothalamus) Stomach protect mucosa Platelets aggregation Kidney vasodilation
  • 39. Indications for administration of non- narcotic analgesics  headache  toothache  backache  neuralgias  pulled muscles  joint pain  dysmenorrhea for potentiating of their action – combinations paracetamol with codeine, metamizol with dimedrol, metamizol with codeine
  • 40. Applications in Dentistry • Toothache • Post extraction pain • Periodontitis • Neuritis • Stomatitis • Arthritis • Local usage as keratoplatic agents for hyperkeratosis, hyperesthesia
  • 41. Paracetamol (Acetaminophen) • analgesic and antipyretic drug • maximal effect if the drug is introduced orally – after 2 hours, lasts approximately for 4 hours • in case of durable administration of big doses – damaging of liver and kidneys, production of met-hemoglobin
  • 42. Paracetamol (Acetaminophen) N-Acetyl-P-Aminophenol Classification: analgesic, antipyretic, misc. not an NSAID Mechanism: inhibits prostaglandin synthesis via CNS inhibition of COX (not peripheral)- doesn’t promote ulcers, bleeding or renal failure; peripherally blocks generation of pain impulses, inhibits hypothalamic heat-regulation center
  • 45. Pharmacokinetics: Paracetamol Metabolism: major and minor pathways Half-life: 1-3 hours Time to peak concentration: 10-60 min Treatment for overdose: Acetylcysteine
  • 46. Paracetamol : Liver Metabolism 1. Major pathway —Majority of drug is metabolized to produce a non-toxic metabolite 2. Minor pathway —Produces a highly reactive intermediate (acetylimidoquinone) that conjugates with glutathione and is inactivated. •At toxic PARACETAMOL levels, minor pathway metabolism cannot keep up (liver’s supply of glutathione is limited), causing an increase in the reactive intermediate which leads to hepatic toxicity and necrosis
  • 47. Acetylsalicylic acid  Blocks irreversibly COX  As antipyretic and analgesic drug – 0,25 and 0,5 g per time  As an anti-inflammatory – 3-4 g per day (for arthritis, myocarditis, pleuritis, bronchitis etc.  As platelets inhibitor - for prophylaxis of thrombus- formation (in case of ischemic heart disease, thrombophlebitis etc.) – daily dose – 80-100 mg
  • 48. Pharmacokinetics: ASA Absorption: from stomach and intestine Distribution: readily, into most fluids/tissues Metabolism : primarily hepatic •ASA contraindicated for use in children with viral fever –can lead to Reye’s Syndrome •Fatal overdose is possible Similar pharmacokinetics for ibuprofen and related NSAIDs
  • 50. Baralgin (maxigan, spazgan, spazmalgon, trigan) metamizol-sodium +pitophenon hydrochloride+pheniverinium bromide Ampoules tablets suppositories Analgesic and spasmolytic activity
  • 51. Traditional and selective COX-2 inhibitors
  • 52. Ketorolak (ketanov) •according to analgesic activity it prevails over effect of acetylsalicylic acid, indometacin and equals to opioid analgesics •moderate anti-inflammatory, antipyretic and anti-aggregate effects •high effectiveness in case of pain in postoperative period, in oncology, during child delivery, traumas, colic •i/m, i/v, orally NOT indicated for chronic pain syndrome
  • 53. Ketoprophen (ketonal) • strong analgesic, anti-inflammatory and antipyretic agent • administered in case of arthroses and arthritis, ancilizing spondilitis, pain of different genesis (after surgeries, in case of traumas, painful menstruations etc.) • administered orally, intramuscularly, in forms of suppositories and ointments
  • 54. TRAMADOL Analgesic activity is similar to the activity of morphine Abuse potential is low Less respiratory depression Hemodynamic effects are minimal In case of intravenous administration effect develops after 5-10 min, if administered orally – after 30-40 min, action lasts for 3-5 hours. Tramadol possesses agonist actions at the μ-opioid receptor and affects reuptake at the noradrenergic and serotonergic systems
  • 55. ADMINISTRATION OF TRAMADOL 1. Surgery, traumatology, gynecology, neurology, urology, oncology 2. For all kinds of acute and chronic pain of moderate and considerable intensity, including neuralgias, postoperative, traumatic pain diagnostic and therapeutic interventions oncologic pathology

Editor's Notes

  1. A protective mechanism to warn of damage or the presence of disease
  2. The structures that take part in perception of pain: thalamus, hypothalamus, reticular formation, limbic system, occipital and frontal areas of cortex System which conducts and perceives pain - nociceptive
  3. Major Sources of Pain
  4. Opium (poppy tears, lachryma papaveris) is the dried latex obtained from opium poppies (Papaver somniferum). Opium contains up to 12% morphine, an opiate alkaloid, like codeine, papaverine noscarpine (benzoisochinolon derivatives)
  5. An opium-based elixir has been ascribed to alchemists of Byzantine times,. Around 1522, Paracelsus made reference to an opium-based elixir which he called, laudanum from the Latin word laudare meaning "to praise."
  6. Morpheus (pronounced /ˈmɔr.fjuːs/; Greek: "he who shapes [dreams]") is the Greek god of dreams and sleep. Morphine was isolated from opium in the early 1800’s and since then has been the most effective treatment for severe pain
  7. Opioid receptors are a group of G-protein coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin.
  8. Trimeperidine is an opioid analgesic that is an analogue of prodine (meperidine). It was developed in or around 1954 in the USSR during research into the related drug pethidine.
  9. a form of analgesia achieved by the concurrent administration of a neuroleptic such as droperidol and an analgesic such as fentanyl. Anxiety, motor activity, and sensitivity to painful stimuli are reduced; the person is quiet and indifferent to surroundings
  10. Although NSAIDs are the established drugs of first choice for the management of mild-to-moderate dental and postoperative pain, at times the oral narcotic analgesics must be used to treat the more severe intensities of pain.
  11. Reye's syndrome is a potentially fatal disease that causes numerous detrimental effects to many organs, especially the brain and liver, as well as causing hypoglycemia.[1] The exact cause is unknown, and while it has been associated with aspirin consumption by children with viral illness, it also occurs in the absence of aspirin use.
  12. It remained freely available worldwide until the 1970s, when it was discovered that the drug carries a small risk of causing agranulocytosis - a potentially fatal condition. Controversy remains regarding the level of risk. Several national medical authorities have banned metamizole either totally or have restricted it to be available only on prescription, while others have maintained its availability over the counter.